DXB

DIMERIX FPO [DXB]
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is headquartered in Fitzroy, Australia.
Healthcare · ASX Small Cap
$0.2900 +0.0%

Updated 3 Sep 2026 · Signals refresh every scan

Appeared in 2 consecutive scansFirst seen: 2026-02-25
Get alerts when DXB triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track DXB — Free

Active Signals

Bullish Signals

  • Smart money may be accumulating — volume is flowing in even though price hasn't moved yet
  • Cash positive / operating cashflow positive
  • Strong revenue growth (+636%)
  • EPS estimates revised upward (+10pts)
  • Sentiment is mixed — no strong consensus either way
  • Revenue growing at +636% — the top line is moving in the right direction
  • The bigger volume days are the up days — volume-weighted momentum is positive (4.52%/day)
  • Beneish M-Score 7.74 > -1.78: likely earnings manipulation
  • RBA hiking (-3pts)

Risk Signals

  • Below the 200-day average — the long-term trend is still working against it
  • Deeply negative margins (-220%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Long-term momentum is negative — down 42% over the past year
Ask Scout AI about DXB
"What's driving DXB today?" "How does DXB compare to peers?" "Key risks for DXB?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NEGATIVE Trading Halt
NONE Appendix 4G and Corporate Governance Statement
NONE Dimerix Receives US$10M Upfront Payment from Everest
NONE Dimerix Assumes Sponsorship of US IND for New Asset DMX-652
LOW Appendix 4E and 2026 Annual Report

Recent ASX Announcements

2026-09-01 Trading Halt PRICE SENSITIVE
2026-08-26 Appendix 4G and Corporate Governance Statement
2026-08-26 Appendix 4E and 2026 Annual Report PRICE SENSITIVE
2026-08-19 Dimerix Receives US$10M Upfront Payment from Everest PRICE SENSITIVE
2026-08-16 Dimerix Assumes Sponsorship of US IND for New Asset DMX-652 PRICE SENSITIVE

Key Metrics

$174.1M
Market Cap
1.0M
Avg Volume
0.5x
Vol Ratio
$0.16 — $0.67
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-594.5%
ROE
-219.9%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 78%
LLeader vs LaggardpassRS: 38
IInstitutional SponsorshipweakInst: 3%
MMarket DirectionneutralNeutral

Sector: Healthcare

113 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
REG -27.0%CAN +25.0%BIT -20.0%MEM +20.0%CMP -14.6%
Compare:DXB vs REGDXB vs CANDXB vs BIT
Scout Pro — Deeper Analysis for DXB
Try Pro free for 30 days
Share this analysis

Track DXB and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required